# Clinical trial results:
# A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)

## Summary

| | |
|---|---|
| EudraCT number | 2017-002871-24 |
| Trial protocol | BE |
| Global end of trial date | 13 October 2021 |

### Results information

| | |
|---|---|
| Result version number | v1 |
| This version publication date | 03 June 2022 |
| First version publication date | 03 June 2022 |
| Summary attachment (see zip file) | CSR synopsis (Synopsis_AG019-T1D.pdf)<br>Figure and tables synopsis (Figure and tables for EudraCT.pdf) |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | AG019-T1D-101 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03751007 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Precigen ActoBio T1D, LLC |
| Sponsor organisation address | 20374 Seneca Meadows Parkway, Germantown, MD 20876, United States, |
| Public contact | Sven Blomme, Precigen ActoBio, abt.info@actobio.com |
| Scientific contact | Sven Blomme, Precigen ActoBio, abt.info@actobio.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 15 November 2021 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 13 October 2021 |
| Global end of trial reached? | Yes |
| Global end of trial date | 13 October 2021 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety and tolerability of different doses of AG019 alone as well as in association with teplizumab.

Protection of trial subjects:

Trial participants were protected by implementing safety measures for recruitment (staggered recruitment, data review by edical monitor before enrolling the next staggered patient), DSMB data review before opening the next cohort for recruitment, and close follow-up by site, medical monitor and DSMB (including scheduled data reviews).

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 20 October 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Belgium: 12 |
| Country: Number of subjects enrolled | United States: 33 |
| Worldwide total number of subjects | 45 |
| EEA total number of subjects | 12 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 19 |
| Adults (18-64 years) | 26 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

AG019 monotherapy cohorts: a total of 8 single dose patients and 19 repeat dose patients
AG019/teplizumab combination cohorts: a total of 18 patients

### Pre-assignment

Screening details:

Key eligibility criteria (to assess within 28d of treatment start):
- 18-40y, or 12-17y
- diagnosis of diabetes according to ADA criteria
- positive for at least 1 T1D autoantibody
- treatment to be started within 150 days of diagnosis
- at least 0.2 nmol/L of C-peptide following mixed meal tolerance test
- No active infections

### Period 1

| | |
|---|---|
| Period 1 title | overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |

Blinding implementation details:

The trial consisted of 2 phases.
Phase 1b was open label. 4 AG019 monotherapy cohorts were sequentially opened (ascending dose groups and descending age groups). Each cohort enrolled 2 single dose patients and up to 6 repeat dose patients.
Phase 2a was double blind (randomization ratio 4:1). 2 AG019/teplizumab combination cohorts were sequentially opened (descending age groups). in each cohort, 2 open label patients were enrolled prior to opening the double blind portion.

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | No |
| **Arm title** | PHASE 1B - Single Low Dose - Adult |

Arm description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | AG019 Single Low Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a single low dose (one-day dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 1B - Single High Dose - Adult |

Arm description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability.
After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | AG019 Single High Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a single high dose (one-day dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 1B - Repeat Low Dose - Adult |

Arm description:

In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. in addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | AG019 Repeat Low Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a repeated low dose (8-week dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 1B - Repeat High Dose - Adult |

Arm description:

In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | AG019 Repeat High Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 1B - Single Low Dose - Adolescent |

Arm description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | AG019 Single Low Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a single low dose (one-day dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 1B - Single High Dose - Adolescent |

Arm description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | AG019 Single High Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a single high dose (one-day dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 1B - Repeat Low Dose - Adolescent |

Arm description:

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | AG019 Repeat Low Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a repeated low dose (8-week dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 1B - Repeat High Dose - Adolescent |

Arm description:

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. In addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | AG019 Repeat High Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| **Arm title** | PHASE 2A - Active AG019/teplizumab - Adults |

Arm description:

A total of 10 adult (18-40y) patients was enrolled into this arm.
The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.
Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).
After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | AG019 Repeat High Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| Investigational medicinal product name | Teplizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for dispersion for infusion |
| Routes of administration | Infusion , Intravenous use |

Dosage and administration details:

Teplizumab was administered as a 12-day infusion cycle, during the first 12 days of AG019 treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:
- Day 1: 106 µg/m²
- Day 2: 425 µg/m²
- Day 3-12: 850 µg/m²

| | |
|---|---|
| **Arm title** | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults |

Arm description:

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.
Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).
All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | AG019-Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019-placebo was administered for 8 weeks at a daily dose of 3 capsules in the morning and 3 capsules in the evening. Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| Investigational medicinal product name | Teplizumab-placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for dispersion for infusion |
| Routes of administration | Infusion , Intravenous use |

Dosage and administration details:

Teplizumab-placebo was administered as a 12-day infusion cycle, during the first 12 days of AG019-placebo treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:
- Day 1: 106 µg/m²
- Day 2: 425 µg/m²
- Day 3-12: 850 µg/m²

Note: teplizumab-placebo did not contain active ingredient, but as the double-blind placebo vials were formulated in an identical way as the active treatment, identical calculations were used to determine the

appropriate infusion voumes.

| **Arm title** | PHASE 2A - Active AG019/teplizumab - Adolescents |
|---|---|

Arm description:

5 adolescent (12-17y) patients were enrolled into this arm.
The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab. Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).
After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 5 active patients and 1 placebo patient

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | AG019 Repeat High Dose |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| Investigational medicinal product name | Teplizumab |
|---|---|
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for dispersion for infusion |
| Routes of administration | Infusion , Intravenous use |

Dosage and administration details:

Teplizumab was administered as a 12-day infusion cycle, during the first 12 days of AG019 treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:
- Day 1: 106 µg/m²
- Day 2: 425 µg/m²
- Day 3-12: 850 µg/m²

| **Arm title** | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|

Arm description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 1 patient was randomized to receive AG019-placebo and teplizumab-placebo.
Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 - placebo treatment).
Follow-up was planned till 12 months (8 weeks of treatment plus 10 months of post treatment follow-up), however, the patient was lost to follow-up after the 9 months follow-up visit.
Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 5 active patients and 1 placebo patient.

| Arm type | Placebo |
|---|---|

| | |
|---|---|
| Investigational medicinal product name | AG019-Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gastro-resistant capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

In this arm, AG019-placebo was administered for 8 weeks at a daily dose of 3 capsules in the morning and 3 capsules in the evening. Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

| | |
|---|---|
| Investigational medicinal product name | Teplizumab-placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for dispersion for infusion |
| Routes of administration | Infusion , Intravenous use |

Dosage and administration details:

Teplizumab-placebo was administered as a 12-day infusion cycle, during the first 12 days of AG019-placebo treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:

- Day 1: 106 µg/m²
- Day 2: 425 µg/m²
- Day 3-12: 850 µg/m²

Note: teplizumab-placebo did not contain active ingredient, but as the double-blind placebo vials were formulated in an identical way as the active treatment, identical calculations were used to determine the appropriate infusion voumes.

| **Number of subjects in period 1** | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult |
|---|---|---|---|
| Started | 2 | 2 | 5 |
| Completed | 2 | 2 | 5 |
| Not completed | 0 | 0 | 0 |
| Consent withdrawn by subject | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Lost to follow-up | - | - | - |

| **Number of subjects in period 1** | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent |
|---|---|---|---|
| Started | 5 | 2 | 2 |
| Completed | 4 | 2 | 2 |
| Not completed | 1 | 0 | 0 |
| Consent withdrawn by subject | 1 | - | - |
| Adverse event, non-fatal | - | - | - |
| Lost to follow-up | - | - | - |

| **Number of subjects in period 1** | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent | PHASE 2A - Active AG019/teplizumab - Adults |
|---|---|---|---|
| Started | 4 | 5 | 10 |
| Completed | 4 | 4 | 10 |
| Not completed | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Consent withdrawn by subject | - | 1 | - |
| Adverse event, non-fatal | - | - | - |
| Lost to follow-up | - | - | - |

| **Number of subjects in period 1** | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|
| Started | 2 | 5 | 1 |
| Completed | 2 | 4 | 0 |
| Not completed | 0 | 1 | 1 |
| Consent withdrawn by subject | - | - | - |
| Adverse event, non-fatal | - | 1 | - |
| Lost to follow-up | - | - | 1 |

## Baseline characteristics

### Reporting groups

| Reporting group title | PHASE 1B - Single Low Dose - Adult |
|---|---|

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Single High Dose - Adult |
|---|---|

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability.
After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Repeat Low Dose - Adult |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. in addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Repeat High Dose - Adult |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Single Low Dose - Adolescent |
|---|---|

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Single High Dose - Adolescent |
|---|---|

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Repeat Low Dose - Adolescent |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. In addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 2A - Active AG019/teplizumab - Adults |
|---|---|

Reporting group description:

A total of 10 adult (18-40y) patients was enrolled into this arm.
The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.
Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).
After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

| Reporting group title | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults |
|---|---|

Reporting group description:

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.
Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).
All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

| Reporting group title | PHASE 2A - Active AG019/teplizumab - Adolescents |
|---|---|

Reporting group description:

5 adolescent (12-17y) patients were enrolled into this arm.

The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab. Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment). After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 5 active patients and 1 placebo patient

| Reporting group title | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|

Reporting group description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 1 patient was randomized to receive AG019-placebo and teplizumab-placebo.
Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 - placebo treatment).
Follow-up was planned till 12 months (8 weeks of treatment plus 10 months of post treatment follow-up), however, the patient was lost to follow-up after the 9 months follow-up visit.
Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 5 active patients and 1 placebo patient.

| **Reporting group values** | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult |
|---|---|---|---|
| Number of subjects | 2 | 2 | 5 |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 2 | 2 | 5 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous<br>Units: years | | | |
| median | 38.0 | 19.5 | 26.0 |
| standard deviation | ± 5.7 | ± 2.1 | ± 8.9 |
| Gender categorical<br>Units: Subjects | | | |
| Female | 0 | 1 | 1 |
| Male | 2 | 1 | 4 |
| Ethnicity<br>Units: Subjects | | | |
| Hispanic or latino | 0 | 1 | 0 |
| Not hispanic or latino | 2 | 1 | 5 |
| baseline serological cytomegalovirus positivity<br>Units: Subjects | | | |
| Negative | 2 | 2 | 5 |
| Positive | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Missing | 0 | 0 | 0 |
| baseline serological Epstein-Barr virus positivity<br>Units: Subjects | | | |
| Negative | 2 | 2 | 2 |
| Positive | 0 | 0 | 3 |
| Autoantibody positivity - GAD65<br>Units: Subjects | | | |
| Negative | 0 | 0 | 0 |
| Positive | 1 | 2 | 5 |
| Missing | 1 | 0 | 0 |
| Autoantibody positivity - IA-2<br>Units: Subjects | | | |
| Negative | 1 | 1 | 2 |
| Positive | 0 | 1 | 2 |
| Missing | 1 | 0 | 1 |
| Autoantibody positivity - ZnT8<br>Units: Subjects | | | |
| Negative | 0 | 1 | 0 |
| Positive | 1 | 1 | 2 |
| Missing | 1 | 0 | 3 |
| Autoantibody positivity - Insulin<br>Units: Subjects | | | |
| Negative | 1 | 1 | 2 |
| Positive | 0 | 1 | 3 |
| Missing | 1 | 0 | 0 |
| Inuslin required at baseline<br>Units: Subjects | | | |
| Yes | 1 | 2 | 5 |
| No | 1 | 0 | 0 |
| Baseline HbA1c<br>Units: percent | | | |
| arithmetic mean | 0 | 0 | 6.38 |
| standard deviation | ± 0 | ± 0 | ± 0.56 |
| time from diagnosis to treatment<br>Units: days | | | |
| arithmetic mean | 84.5 | 45.5 | 91.0 |
| standard deviation | ± 44.5 | ± 20.5 | ± 38.2 |
| Baseline IDAA1c<br>Units: none | | | |
| arithmetic mean | 0.00 | 0.00 | 7.385 |
| standard deviation | ± 0.00 | ± 0.00 | ± 1.303 |
| Fasting C-peptide<br>Units: nmol/L | | | |
| arithmetic mean | 0.00 | 0.00 | 0.27 |
| standard deviation | ± 0.00 | ± 0.00 | ± 0.15 |
| Peak stimulated C-peptide<br>Units: nmol/L | | | |
| arithmetic mean | 0 | 0 | 0.92 |
| standard deviation | ± 0 | ± 0 | ± 0.35 |
| 2H C-peptide AUC<br>Units: nmol/L | | | |

| | | | |
|---|---|---|---|
| arithmetic mean | 0.000 | 0.000 | 0.62 |
| standard deviation | ± 0.000 | ± 0.000 | ± 0.28 |
| Total daily insulin use | | | |
| Units: IU/kg/d | | | |
| arithmetic mean | 0.000 | 0.00 | 0.23 |
| standard deviation | ± 0.00 | ± 0.00 | ± 0.18 |

| **Reporting group values** | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent |
|---|---|---|---|
| Number of subjects | 5 | 2 | 2 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 2 | 2 |
| Adults (18-64 years) | 5 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous | | | |
| Units: years | | | |
| median | 22.0 | 16.5 | 17.0 |
| standard deviation | ± 7.4 | ± 0.7 | ± 0.0 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 2 | 2 | 0 |
| Male | 3 | 0 | 2 |
| Ethnicity | | | |
| Units: Subjects | | | |
| Hispanic or latino | 1 | 0 | 1 |
| Not hispanic or latino | 4 | 2 | 1 |
| baseline serological cytomegalovirus positivity | | | |
| Units: Subjects | | | |
| Negative | 5 | 2 | 2 |
| Positive | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 |
| baseline serological Epstein-Barr virus positivity | | | |
| Units: Subjects | | | |
| Negative | 4 | 2 | 2 |
| Positive | 1 | 0 | 0 |
| Autoantibody positivity - GAD65 | | | |
| Units: Subjects | | | |
| Negative | 0 | 0 | 0 |
| Positive | 5 | 1 | 1 |
| Missing | 0 | 1 | 1 |
| Autoantibody positivity - IA-2 | | | |

| Units: Subjects | | | |
|---|---|---|---|
| Negative | 1 | 0 | 0 |
| Positive | 4 | 1 | 0 |
| Missing | 0 | 1 | 2 |
| Autoantibody positivity - ZnT8<br>Units: Subjects | | | |
| Negative | 2 | 0 | 0 |
| Positive | 2 | 0 | 0 |
| Missing | 1 | 2 | 2 |
| Autoantibody positivity - Insulin<br>Units: Subjects | | | |
| Negative | 2 | 0 | 1 |
| Positive | 3 | 0 | 0 |
| Missing | 0 | 2 | 1 |
| Inuslin required at baseline<br>Units: Subjects | | | |
| Yes | 4 | 2 | 2 |
| No | 1 | 0 | 0 |
| Baseline HbA1c<br>Units: percent | | | |
| arithmetic mean | 7.00 | 0 | 0 |
| standard deviation | ± 1.57 | ± 0 | ± 0 |
| time from diagnosis to treatment<br>Units: days | | | |
| arithmetic mean | 100.0 | 146.0 | 113.0 |
| standard deviation | ± 42.2 | ± 4.2 | ± 53.7 |
| Baseline IDAA1c<br>Units: none | | | |
| arithmetic mean | 8.248 | 0.00 | 0.00 |
| standard deviation | ± 2.369 | ± 0.00 | ± 0.00 |
| Fasting C-peptide<br>Units: nmol/L | | | |
| arithmetic mean | 0.38 | 0.00 | 0.00 |
| standard deviation | ± 0.20 | ± 0.00 | ± 0.00 |
| Peak stimulated C-peptide<br>Units: nmol/L | | | |
| arithmetic mean | 1.26 | 0 | 0 |
| standard deviation | ± 1.00 | ± 0 | ± 0 |
| 2H C-peptide AUC<br>Units: nmol/L | | | |
| arithmetic mean | 0.89 | 0.000 | 0.000 |
| standard deviation | ± 0.61 | ± 0.000 | ± 0.000 |
| Total daily insulin use<br>Units: IU/kg/d | | | |
| arithmetic mean | 0.31 | 0.00 | 0.00 |
| standard deviation | ± 0.24 | ± 0.00 | ± 0.00 |

| **Reporting group values** | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent | PHASE 2A - Active AG019/teplizumab - Adults |
|---|---|---|---|
| Number of subjects | 4 | 5 | 10 |

| | | | |
|---|---|---|---|
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 4 | 5 | 0 |
| Adults (18-64 years) | 0 | 0 | 10 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous<br>Units: years | | | |
| median | 14.0 | 14.0 | 26.5 |
| standard deviation | ± 2.2 | ± 1.9 | ± 6.7 |
| Gender categorical<br>Units: Subjects | | | |
| Female | 2 | 3 | 4 |
| Male | 2 | 2 | 6 |
| Ethnicity<br>Units: Subjects | | | |
| Hispanic or latino | 0 | 0 | 0 |
| Not hispanic or latino | 4 | 5 | 10 |
| baseline serological cytomegalovirus positivity<br>Units: Subjects | | | |
| Negative | 3 | 5 | 5 |
| Positive | 1 | 0 | 5 |
| Missing | 0 | 0 | 0 |
| baseline serological Epstein-Barr virus positivity<br>Units: Subjects | | | |
| Negative | 4 | 4 | 4 |
| Positive | 0 | 1 | 6 |
| Autoantibody positivity - GAD65<br>Units: Subjects | | | |
| Negative | 1 | 0 | 0 |
| Positive | 3 | 5 | 10 |
| Missing | 0 | 0 | 0 |
| Autoantibody positivity - IA-2<br>Units: Subjects | | | |
| Negative | 2 | 2 | 5 |
| Positive | 2 | 2 | 3 |
| Missing | 0 | 1 | 2 |
| Autoantibody positivity - ZnT8<br>Units: Subjects | | | |
| Negative | 1 | 1 | 2 |
| Positive | 3 | 3 | 5 |
| Missing | 0 | 1 | 3 |
| Autoantibody positivity - Insulin | | | |

| | | | |
|---|---|---|---|
| Units: Subjects | | | |
| Negative | 1 | 2 | 5 |
| Positive | 1 | 2 | 0 |
| Missing | 2 | 1 | 5 |
| Inuslin required at baseline<br>Units: Subjects | | | |
| Yes | 4 | 5 | 10 |
| No | 0 | 0 | 0 |
| Baseline HbA1c<br>Units: percent | | | |
| arithmetic mean | 6.40 | 6.28 | 6.92 |
| standard deviation | ± 0.51 | ± 0.89 | ± 1.42 |
| time from diagnosis to treatment<br>Units: days | | | |
| arithmetic mean | 95.0 | 126.4 | 101.0 |
| standard deviation | ± 21.3 | ± 19.4 | ± 35.9 |
| Baseline IDAA1c<br>Units: none | | | |
| arithmetic mean | 9.090 | 8.392 | 8.412 |
| standard deviation | ± 1.093 | ± 2.470 | ± 1.725 |
| Fasting C-peptide<br>Units: nmol/L | | | |
| arithmetic mean | 0.33 | 0.27 | 0.18 |
| standard deviation | ± 0.08 | ± 0.14 | ± 0.13 |
| Peak stimulated C-peptide<br>Units: nmol/L | | | |
| arithmetic mean | 0.97 | 0.81 | 0.71 |
| standard deviation | ± 0.45 | ± 0.21 | ± 0.26 |
| 2H C-peptide AUC<br>Units: nmol/L | | | |
| arithmetic mean | 0.78 | 0.57 | 0.48 |
| standard deviation | ± 0.35 | ± 0.13 | ± 0.19 |
| Total daily insulin use<br>Units: IU/kg/d | | | |
| arithmetic mean | 0.67 | 0.53 | 0.37 |
| standard deviation | ± 0.27 | ± 0.46 | ± 0.14 |

| **Reporting group values** | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|
| Number of subjects | 2 | 5 | 1 |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 5 | 1 |
| Adults (18-64 years) | 2 | 0 | 0 |

| | | | |
|---|---|---|---|
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Age continuous<br>Units: years | | | |
| median | 29.0 | 14.0 | 12.0 |
| standard deviation | ± 5.7 | ± 1.1 | ± 0.0 |
| Gender categorical<br>Units: Subjects | | | |
| Female | 1 | 3 | 1 |
| Male | 1 | 2 | 0 |
| Ethnicity<br>Units: Subjects | | | |
| Hispanic or latino | 0 | 0 | 0 |
| Not hispanic or latino | 2 | 5 | 1 |
| baseline serological cytomegalovirus positivity<br>Units: Subjects | | | |
| Negative | 1 | 4 | 1 |
| Positive | 1 | 0 | 0 |
| Missing | 0 | 1 | 0 |
| baseline serological Epstein-Barr virus positivity<br>Units: Subjects | | | |
| Negative | 0 | 4 | 1 |
| Positive | 2 | 1 | 0 |
| Autoantibody positivity - GAD65<br>Units: Subjects | | | |
| Negative | 0 | 2 | 0 |
| Positive | 2 | 3 | 1 |
| Missing | 0 | 0 | 0 |
| Autoantibody positivity - IA-2<br>Units: Subjects | | | |
| Negative | 1 | 1 | 0 |
| Positive | 1 | 4 | 1 |
| Missing | 0 | 0 | 0 |
| Autoantibody positivity - ZnT8<br>Units: Subjects | | | |
| Negative | 0 | 0 | 0 |
| Positive | 0 | 3 | 0 |
| Missing | 2 | 2 | 1 |
| Autoantibody positivity - Insulin<br>Units: Subjects | | | |
| Negative | 1 | 3 | 0 |
| Positive | 1 | 1 | 1 |
| Missing | 0 | 1 | 0 |
| Inuslin required at baseline<br>Units: Subjects | | | |
| Yes | 2 | 5 | 1 |
| No | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Baseline HbA1c | | | |
| Units: percent | | | |
| arithmetic mean | 7.35 | 7.14 | 8.40 |
| standard deviation | ± 3.04 | ± 2.43 | ± 0.00 |
| time from diagnosis to treatment | | | |
| Units: days | | | |
| arithmetic mean | 70.0 | 122.6 | 90.0 |
| standard deviation | ± 15.6 | ± 36.3 | ± 0.00 |
| Baseline IDAA1c | | | |
| Units: none | | | |
| arithmetic mean | 8.530 | 9.605 | 10.640 |
| standard deviation | ± 4.540 | ± 2.583 | ± 0.00 |
| Fasting C-peptide | | | |
| Units: nmol/L | | | |
| arithmetic mean | 0.36 | 0.25 | 0.16 |
| standard deviation | ± 0.22 | ± 0.06 | ± 0.00 |
| Peak stimulated C-peptide | | | |
| Units: nmol/L | | | |
| arithmetic mean | 1.10 | 0.76 | 0.28 |
| standard deviation | ± 0.11 | ± 0.29 | ± 0.00 |
| 2H C-peptide AUC | | | |
| Units: nmol/L | | | |
| arithmetic mean | 0.73 | 0.57 | 0.25 |
| standard deviation | ± 0.01 | ± 0.21 | ± 0.00 |
| Total daily insulin use | | | |
| Units: IU/kg/d | | | |
| arithmetic mean | 0.30 | 0.51 | 0.56 |
| standard deviation | ± 0.37 | ± 0.18 | ± 0.00 |

| **Reporting group values** | Total | | |
|---|---|---|---|
| Number of subjects | 45 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 19 | | |
| Adults (18-64 years) | 26 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |
| Age continuous | | | |
| Units: years | | | |
| median | | | |
| standard deviation | - | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 20 | | |
| Male | 25 | | |

| | | | |
|---|---|---|---|
| Ethnicity<br>Units: Subjects | | | |
| Hispanic or latino | 3 | | |
| Not hispanic or latino | 42 | | |
| baseline serological cytomegalovirus positivity<br>Units: Subjects | | | |
| Negative | 37 | | |
| Positive | 7 | | |
| Missing | 1 | | |
| baseline serological Epstein-Barr virus positivity<br>Units: Subjects | | | |
| Negative | 31 | | |
| Positive | 14 | | |
| Autoantibody positivity - GAD65<br>Units: Subjects | | | |
| Negative | 3 | | |
| Positive | 39 | | |
| Missing | 3 | | |
| Autoantibody positivity - IA-2<br>Units: Subjects | | | |
| Negative | 16 | | |
| Positive | 21 | | |
| Missing | 8 | | |
| Autoantibody positivity - ZnT8<br>Units: Subjects | | | |
| Negative | 7 | | |
| Positive | 20 | | |
| Missing | 18 | | |
| Autoantibody positivity - Insulin<br>Units: Subjects | | | |
| Negative | 19 | | |
| Positive | 13 | | |
| Missing | 13 | | |
| Inuslin required at baseline<br>Units: Subjects | | | |
| Yes | 43 | | |
| No | 2 | | |
| Baseline HbA1c<br>Units: percent<br>arithmetic mean<br>standard deviation | -<br>- | | |
| time from diagnosis to treatment<br>Units: days<br>arithmetic mean<br>standard deviation | -<br>- | | |
| Baseline IDAA1c<br>Units: none<br>arithmetic mean<br>standard deviation | -<br>- | | |
| Fasting C-peptide | | | |

| | | | |
|---|---|---|---|
| Units: nmol/L<br>arithmetic mean<br>standard deviation | - | | |
| Peak stimulated C-peptide<br>Units: nmol/L<br>arithmetic mean<br>standard deviation | - | | |
| 2H C-peptide AUC<br>Units: nmol/L<br>arithmetic mean<br>standard deviation | - | | |
| Total daily insulin use<br>Units: IU/kg/d<br>arithmetic mean<br>standard deviation | - | | |

## End points

### End points reporting groups

| Reporting group title | PHASE 1B - Single Low Dose - Adult |
|---|---|

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Single High Dose - Adult |
|---|---|

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability.
After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Repeat Low Dose - Adult |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. in addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Repeat High Dose - Adult |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Single Low Dose - Adolescent |
|---|---|

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Single High Dose - Adolescent |
|---|---|

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Repeat Low Dose - Adolescent |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. In addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 2A - Active AG019/teplizumab - Adults |
|---|---|

Reporting group description:

A total of 10 adult (18-40y) patients was enrolled into this arm.
The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.
Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).
After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

| Reporting group title | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults |
|---|---|

Reporting group description:

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.
Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).
All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

| Reporting group title | PHASE 2A - Active AG019/teplizumab - Adolescents |
|---|---|

Reporting group description:

5 adolescent (12-17y) patients were enrolled into this arm.

The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab. Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment). After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 5 active patients and 1 placebo patient

| Reporting group title | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|

Reporting group description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 1 patient was randomized to receive AG019-placebo and teplizumab-placebo.
Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 - placebo treatment).
Follow-up was planned till 12 months (8 weeks of treatment plus 10 months of post treatment follow-up), however, the patient was lost to follow-up after the 9 months follow-up visit.
Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 5 active patients and 1 placebo patient.

| Subject analysis set title | Safety Analysis Set |
|---|---|
| Subject analysis set type | Safety analysis |

Subject analysis set description:

The safety population will include all patients who received at least one dose of AG019. Only patients with clear documentation that no study medication was received may be excluded from analysis. Patients were analyzed according to dose received. This population is used for all data summaries.

| Subject analysis set title | PD-ITT |
|---|---|
| Subject analysis set type | Sub-group analysis |

Subject analysis set description:

The Pharmacodynamic Intention To Treat (PD-ITT) Analysis Set. All patients in the repeat dose and combination cohorts who received at least one dose of AG019 were included in the PD-ITT analysis set.

| Subject analysis set title | PD-PP |
|---|---|
| Subject analysis set type | Sub-group analysis |

Subject analysis set description:

The Pharmacodynamic Per Protocol (PD-PP) Analysis Set. All data from patients in the repeat dose and combination cohorts who received at least 75% of the scheduled doses of AG019 and at least one dose of teplizumab in the combination cohorts and had no major protocol deviations affecting the main PD endpoints at the time point of data collection were included in the PD-PP analysis set.
Refer to the SAP for details on compliance calculation and designation of major PDs affecting the main PD endpoints.

| Subject analysis set title | PK-ITT |
|---|---|
| Subject analysis set type | Sub-group analysis |

Subject analysis set description:

The Pharmacokinetic Intention To Treat (PK-ITT) Analysis Set. All patients in the repeat dose and combination cohorts who received at least one dose of AG019 were included in the PK-ITT analysis set.

| Subject analysis set title | PK-PP |
|---|---|
| Subject analysis set type | Sub-group analysis |

Subject analysis set description:

The Pharmacokinetic Per Protocol (PK-PP) Analysis Set. All data from patients in the repeat dose and combination cohorts who received at least 75% of the scheduled doses of AG019 and at least one dose of teplizumab in the combination cohorts and had no major protocol deviations affecting the main PK endpoints at the time point of data collection are included in the PK-PP analysis set.

## Primary: incidence of treatment emergent adverse events up to 6 months

| End point title | incidence of treatment emergent adverse events up to 6 months[1] |
|---|---|

End point description:

The incidence of TEAE reported up to the 6-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.

| End point type | Primary |
|---|---|

End point timeframe:

up to 6 months follow-up

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics was used, no formal comparisons have been made. The primary endpoint is defined as the incidence of TEAE up to 6 months; but incidence rates were not statistically compared between groups.

| **End point values** | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 5 |
| Units: number of TEAE | 1 | 1 | 6 | 19 |

| **End point values** | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 4 | 5 |
| Units: number of TEAE | 1 | 1 | 28 | 19 |

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 5 | 1 |
| Units: number of TEAE | 91 | 25 | 22 | 1 |

| **End point values** | Safety Analysis Set | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 45 | | | |
| Units: number of TEAE | 215 | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Presence of AG019 L. lactis bacteria in whole blood

| End point title | Presence of AG019 L. lactis bacteria in whole blood[2] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Blood sample at screening, during treatment (Day 12 and Day 56) and post treatment (Day 90; 34 days after last treatment)

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| **End point values** | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 4 | 5 |
| Units: Yes/No | 0 | 0 | 0 | 0 |

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 4 | 1 |
| Units: Yes/No | 0 | 0 | 0 | 0 |

| **End point values** | PK-ITT | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Yes/No | 0 | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Indication for exposure of AG019 secreted hPINS protein in plasma

| End point title | Indication for exposure of AG019 secreted hPINS protein in plasma[3] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Plasma sample at screening, during treatment (Day 12 and Day 56) and post treatment (Day 90; 34

days after last treatment)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| **End point values** | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 4 | 5 |
| Units: Yes/No | 0 | 0 | 0 | 0 |

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 4 | 1 |
| Units: Yes/No | 0 | 0 | 0 | 0 |

| **End point values** | PK-ITT | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Yes/No | 0 | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Indication for exposure of AG019 secreted hIL-10 protein in plasma

| End point title | Indication for exposure of AG019 secreted hIL-10 protein in plasma[4] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Plasma sample at screening, during treatment (Day 12 and Day 56) and post treatment (Day 90; 34 days after last treatment)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 4 | 5 |
| Units: Yes/No | 0 | 0 | 0 | 0 |

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 4 | 1 |
| Units: Yes/No | 0 | 0 | 0 | 0 |

| End point values | PK-ITT | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 36 | | | |
| Units: Yes/No | 0 | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Presence of AG019 L.lactis bacteria in fecal excretion

| End point title | Presence of AG019 L.lactis bacteria in fecal excretion[5] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Fecal sample at screening, on the last day of treatment (at Day 56) and every 2 days thereafter (Day 58, 60, 62 and 64) for a total of 5 sampling points

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat High Dose - Adolescent | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 4[6] | 10 | 2 |
| Units: Yes/No | 3 | 3 | 9 | 0 |

Notes:

[6] - 1 subject was unwilling to provide samples

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents | PK-ITT | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 3[7] | 1 | 25 | |
| Units: Yes/No | 3 | 0 | 18 | |

Notes:

[7] - 1 subject stopped after one dose of AG019
1 subject was unable to provide samples

## Statistical analyses

No statistical analyses for this end point

## Secondary: hypoglycemic events - before treatment

| End point title | hypoglycemic events - before treatment[8] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

before treatment

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| **End point values** | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 4 | 5 |
| Units: number of events | | | | |
| level 2 | 5 | 1 | 2 | 3 |
| level 3 | 0 | 0 | 0 | 0 |
| unknown | 0 | 0 | 0 | 0 |

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 5 | 1 |
| Units: number of events | | | | |
| level 2 | 30 | 1 | 0 | 0 |
| level 3 | 1 | 0 | 0 | 0 |

| | | | | |
|---|---|---|---|---|
| unknown | 5 | 0 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: hypoglycemic events - during treatment

| End point title | hypoglycemic events - during treatment[9] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

during treatment

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 4 | 5 |
| Units: number of events | | | | |
| level 2 | 10 | 4 | 3 | 7 |
| level 3 | 0 | 0 | 1 | 0 |
| unknown | 0 | 2 | 1 | 2 |

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 5 | 1 |
| Units: number of events | | | | |
| level 2 | 51 | 3 | 2 | 1 |
| level 3 | 2 | 0 | 1 | 0 |
| unknown | 12 | 2 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: hypoglycemic events - after treatment

| End point title | hypoglycemic events - after treatment[10] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

after treatment up to 12 months

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 4 | 5 |
| Units: number of events | | | | |
| level 2 | 51 | 0 | 3 | 126 |
| level 3 | 0 | 0 | 0 | 1 |
| unknown | 0 | 0 | 6 | 15 |

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 5 | 1 |
| Units: number of events | | | | |
| level 2 | 46 | 11 | 3 | 0 |
| level 3 | 1 | 0 | 0 | 0 |
| unknown | 46 | 1 | 0 | 0 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Incidence of treatment emergent adverse events according to severity

| End point title | Incidence of treatment emergent adverse events according to severity |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:
entire study (through 12 months follow-up)

| **End point values** | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 5 |
| Units: number of events | | | | |
| Grade 1 | 1 | 1 | 8 | 24 |
| Grade 2 | 0 | 0 | 2 | 7 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |

| **End point values** | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 4 | 5 |
| Units: number of events | | | | |
| Grade 1 | 1 | 1 | 27 | 27 |
| Grade 2 | 0 | 0 | 9 | 3 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 5 | 1 |
| Units: number of events | | | | |
| Grade 1 | 84 | 27 | 16 | 2 |
| Grade 2 | 35 | 10 | 9 | 0 |
| Grade 3 | 7 | 0 | 1 | 0 |
| Grade 4 | 1 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |

**Statistical analyses**

No statistical analyses for this end point

## Secondary: Incidence of treatment emergent adverse events according to relatedness

| End point title | Incidence of treatment emergent adverse events according to relatedness |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

entire study (through 12 months follow-up)

| End point values | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 5 |
| Units: number of events | | | | |
| reasonably related | 1 | 1 | 0 | 4 |
| not reasonably related | 0 | 0 | 10 | 27 |

| End point values | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 4 | 5 |
| Units: number of events | | | | |
| reasonably related | 0 | 1 | 4 | 3 |
| not reasonably related | 1 | 0 | 32 | 27 |

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 5 | 1 |
| Units: number of events | | | | |
| reasonably related | 41 | 22 | 1 | 0 |
| not reasonably related | 86 | 15 | 25 | 2 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Total daily insulin use

| End point title | Total daily insulin use[11] |
|---|---|

End point description:

note: as no standard deviation was calculated, the values are entered as zero to avoid validation conflicts.

| End point type | Secondary |
|---|---|

End point timeframe:

at regular time points (represented by the different categories) throughout the study.

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 4 | 4 | 4 |
| Units: IU/kg/day | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 1 | 0.3 (± 0) | 0.23 (± 0) | 0.7 (± 0) | 0.27 (± 0) |
| Day 12 | 0.24 (± 0) | 0.2 (± 0) | 0.56 (± 0) | 0.21 (± 0) |
| Day 56 | 0.29 (± 0) | 0.23 (± 0) | 0.65 (± 0) | 0.26 (± 0) |
| Day 90 | 0.35 (± 0) | 0.26 (± 0) | 0.61 (± 0) | 0.35 (± 0) |
| Day 180 | 0.36 (± 0) | 0.28 (± 0) | 0.58 (± 0) | 0.50 (± 0) |
| Day 360 | 0.46 (± 0) | 0.34 (± 0) | 0.65 (± 0) | 0.39 (± 0) |

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 4 | 1 |
| Units: IU/kg/day | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 1 | 0.36 (± 0) | 0.29 (± 0) | 0.5 (± 0) | 0.48 (± 0) |
| Day 12 | 0.4 (± 0) | 0.32 (± 0) | 0.57 (± 0) | 0.3 (± 0) |
| Day 56 | 0.4 (± 0) | 0.36 (± 0) | 0.37 (± 0) | 0.53 (± 0) |
| Day 90 | 0.36 (± 0) | 0.42 (± 0) | 0.46 (± 0) | 0.6 (± 0) |
| Day 180 | 0.39 (± 0) | 0.28 (± 0) | 0.47 (± 0) | 0.55 (± 0) |
| Day 360 | 0.35 (± 0) | 0.34 (± 0) | 0.54 (± 0) | 0 (± 0) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: preproinsulin specific CD8+ T cells

| End point title | preproinsulin specific CD8+ T cells[12] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

3 months (Day 90) and 6 months (Day 180) as represented in the categories

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat High Dose - Adolescent | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 4[13] | 9[14] | 2 |
| Units: log-fold change from baseline | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | -0.137 (± 0.126) | -0.084 (± 0.012) | -0.044 (± 0.125) | 0.007 (± 0.095) |
| Day 180 | -0.047 (± 0.034) | -0.121 (± 0.159) | -0.064 (± 0.098) | -0.148 (± 0.181) |

Notes:

[13] - Day 180: n=2 (2 data points missing)

[14] - Day 180: n=7 (2 data points missing)

| End point values | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 4 | 1 | | |
| Units: log-fold change from baseline | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | -0.095 (± 0.142) | 0.140 (± 0.000) | | |
| Day 180 | -0.179 (± 0.162) | 0.052 (± 0.000) | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Incidence of treatment emergent adverse events up to 12 months

| End point title | Incidence of treatment emergent adverse events up to 12 months |
|---|---|

End point description:

Incidence of all reported TEAE up to the 12-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.

| End point type | Secondary |
|---|---|

End point timeframe:

entire study, up to 12 months

| **End point values** | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 5 |
| Units: number of events | 1 | 1 | 8 | 26 |

| **End point values** | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 4 | 5 |
| Units: number of events | 1 | 1 | 33 | 26 |

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 2 | 5 | 1 |
| Units: number of events | 97 | 26 | 23 | 2 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: HbA1c values over time

| End point title | HbA1c values over time[15] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

every 3 months up to 12 months

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| **End point values** | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 4[16] | 4[17] | 4[18] |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 5.84 (± 0.43) | 5.65 (± 0.57) | 6.33 (± 0.67) | 6.48 (± 1.16) |
| Day 180 | 5.88 (± 0.18) | 5.58 (± 0.41) | 7.17 (± 1.68) | 5.90 (± 0.71) |
| Day 270 | 5.80 (± 0.39) | 5.83 (± 0.61) | 8.65 (± 2.05) | 6.70 (± 1.54) |
| Day 360 | 5.96 (± 0.42) | 6.05 (± 0.31) | 7.08 (± 1.91) | 7.53 (± 1.66) |

Notes:

[16] - Day 270: n=3

[17] - Day 180: n=3
Day 270: n=2

[18] - Day 180: n=2
Day 270 and Day 360: n=3

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 9[19] | 2[20] | 4[21] | 1[22] |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 5.86 (± 0.94) | 6.35 (± 1.48) | 6.40 (± 0.75) | 7.30 (± 0.00) |
| Day 180 | 6.00 (± 1.06) | 7.20 (± 2.97) | 6.35 (± 0.73) | 6.50 (± 0.00) |
| Day 270 | 6.36 (± 0.87) | 9.60 (± 0.00) | 6.27 (± 0.65) | 6.00 (± 0.00) |
| Day 360 | 6.42 (± 0.98) | 9.60 (± 0.00) | 6.58 (± 0.63) | 0.00 (± 0.00) |

Notes:

[19] - Day 180 and Day 270: n=8

[20] - Day 270 and Day 360: n=1

[21] - Day 90 and Day 270: n=3

[22] - Day 360: n=0 (sample not obtained)

| **End point values** | PD-PP | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 33[23] | | | |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 6.09 (± 0.84) | | | |
| Day 180 | 6.18 (± 1.08) | | | |
| Day 270 | 6.51 (± 1.26) | | | |
| Day 360 | 6.62 (± 1.21) | | | |

Notes:

[23] - Day 90: n=32
Day 180: n=29
Day 270: n=26
Day 360: n=30

## Statistical analyses

No statistical analyses for this end point

## Secondary: IDAA1c values over time

| End point title | IDAA1c values over time[24] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

every 3 months up to 12 months

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 4[25] | 4[26] | 4[27] |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 7.24 (± 1.02) | 6.67 (± 0.78) | 8.76 (± 0.93) | 7.87 (± 1.48) |
| Day 180 | 7.34 (± 0.84) | 6.71 (± 0.89) | 9.70 (± 2.54) | 7.96 (± 1.81) |
| Day 270 | 7.38 (± 1.05) | 6.93 (± 0.76) | 12.73 (± 1.60) | 8.58 (± 2.08) |
| Day 360 | 7.78 (± 1.20) | 7.40 (± 0.74) | 9.66 (± 2.49) | 9.08 (± 1.22) |

Notes:

[25] - Day 270: n=3

[26] - Day 180: n=3
Day 270: n=2

[27] - Day 180: n=2
Day 270 and Day 360: n=3

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 9[28] | 2[29] | 4[30] | 1[31] |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 7.23 (± 0.82) | 8.03 (± 3.24) | 8.51 (± 0.04) | 9.70 (± 0.00) |
| Day 180 | 7.61 (± 0.79) | 8.30 (± 4.24) | 8.23 (± 1.28) | 8.70 (± 0.00) |
| Day 270 | 7.81 (± 0.72) | 11.40 (± 0.00) | 8.76 (± 0.42) | 7.44 (± 0.00) |

| | | | | |
|---|---|---|---|---|
| Day 360 | 7.83 (± 0.79) | 12.80 (± 0.00) | 8.72 (± 0.97) | 0.00 (± 0.00) |

Notes:

[28] - Day 180 and Day 270: n=8

[29] - Day 270 and Day 360: n=1

[30] - Day 90 and Day 270: n=2

[31] - Day 360: n=0

| **End point values** | PD-PP | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 31[32] | | | |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 7.65 (± 1.27) | | | |
| Day 180 | 7.85 (± 1.55) | | | |
| Day 270 | 8.31 (± 1.86) | | | |
| Day 360 | 8.42 (± 1.59) | | | |

Notes:

[32] - Day 180: n=29
Day 270: n=25
Day 360: n=30

### Statistical analyses

No statistical analyses for this end point

## Secondary: Mean 2H C-peptide AUC over time

| | |
|---|---|
| End point title | Mean 2H C-peptide AUC over time[33] |

End point description:

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

2H AUC at baseline and at 3, 6 and 12 months as depicted in the categories. Calculated on PD-PP population.

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| **End point values** | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 4 | 4[34] |
| Units: nmol/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 0.619 (± 0.276) | 0.925 (± 0.705) | 0.784 (± 0.350) | 0.631 (± 0.015) |
| Day 90 | 0.514 (± 0.240) | 0.719 (± 0.508) | 0.689 (± 0.395) | 0.573 (± 0.226) |
| Day 180 | 0.592 (± 0.324) | 0.729 (± 0.576) | 0.517 (± 0.199) | 0.432 (± 0.330) |
| Day 360 | 0.418 (± 0.257) | 0.500 (± 0.327) | 0.428 (± 0.134) | 0.512 (± 0.484) |

Notes:

[34] - Day 180: n=3
Day 360: n=2

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10[35] | 2[36] | 4[37] | 1[38] |
| Units: nmol/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 0.483 (± 0.194) | 0.726 (± 0.010) | 0.630 (± 0.183) | 0.247 (± 0.000) |
| Day 90 | 0.544 (± 0.222) | 0.681 (± 0.188) | 0.573 (± 0.144) | 0.253 (± 0.000) |
| Day 180 | 0.517 (± 0.230) | 0.532 (± 0.088) | 0.766 (± 0.148) | 0.191 (± 0.000) |
| Day 360 | 0.464 (± 0.255) | 0.396 (± 0.000) | 0.665 (± 0.160) | 0.000 (± 0.000) |

Notes:

[35] - Day 360: n=9

[36] - Day 360: n=1

[37] - Day 90: n=3

[38] - Day 360: n=0

### Statistical analyses

No statistical analyses for this end point

## Secondary: Percent change from baseline values of mean 2H C-peptide AUC

| End point title | Percent change from baseline values of mean 2H C-peptide AUC[39] |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

3, 6 and 12 months as represented by the categories

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| End point values | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 4 | 4 | 4[40] |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 81.516 (± 11.023) | 78.719 (± 18.248) | 82.995 (± 16.692) | 90.385 (± 34.049) |

| | | | | |
|---|---|---|---|---|
| Day 180 | 91.978 (± 29.620) | 76.631 (± 17.043) | 72.067 (± 23.968) | 67.655 (± 50.038) |
| Day 360 | 61.671 (± 22.054) | 57.570 (± 32.472) | 58.812 (± 13.311) | 79.293 (± 73.862) |

Notes:

[40] - Day 180: n=3
Day 360: n=2

| **End point values** | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10[41] | 2[42] | 4[43] | 1[44] |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 90 | 120.507 (± 45.663) | 93.681 (± 24.610) | 106.876 (± 29.070) | 102.408 (± 0.000) |
| Day 180 | 111.581 (± 35.749) | 73.250 (± 11.021) | 123.805 (± 10.341) | 77.313 (± 0.000) |
| Day 360 | 100.239 (± 35.792) | 53.997 (± 0.000) | 107.863 (± 23.169) | 0.000 (± 0.000) |

Notes:

[41] - Day 360: n=9

[42] - Day 360: n=1

[43] - Day 90: n=3

[44] - Day 360: n=0

### Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage C-peptide responders

| End point title | Percentage C-peptide responders[45] |
|---|---|

End point description:

A patient was designated as responder when his or her C-peptide change from baseline was either non-negative or, if negative, represented a coefficient of variance (CV) less than or equal to 9.7% (Greenbaum et al., 2012)

| End point type | Secondary |
|---|---|

End point timeframe:

percent of patients designated as C-peptide responders at 6 and 12 months

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Single dose cohorts are only part of the safety analysis set and were not considered for PK or PD evaluations.

| **End point values** | PHASE 1B - Repeat Low Dose - Adult | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 4 | 4 | 3[46] |
| Units: percentage | | | | |
| Day 180 | 60 | 50 | 25 | 33 |
| Day 360 | 20 | 25 | 0 | 50 |

Notes:
[46] - Day 360: n=2

| End point values | PHASE 2A - Active AG019/teplizumab - Adults | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10[47] | 2[48] | 4 | 1[49] |
| Units: percentage | | | | |
| Day 180 | 70 | 0 | 100 | 0 |
| Day 360 | 67 | 0 | 100 | 0 |

Notes:
[47] - Day 360: n=9
[48] - Day 360: n=1
[49] - Day 360: n=0

## Statistical analyses

No statistical analyses for this end point

## Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from signature of informed consent until completion of the study (or premature withdrawal).

Adverse event reporting additional description:

All adverse events are listed, regardless of treatment emergence, severity, or relationship to AG019 or teplizumab. The results of the primary endpoint (incidence of TEAE up to 6 months) are outlined in the Endpoints section.

| | |
|---|---|
| Assessment type | Systematic |

## Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 21.0 |

## Reporting groups

| | |
|---|---|
| Reporting group title | PHASE 1B - Single Low Dose - Adult |

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| | |
|---|---|
| Reporting group title | PHASE 1B - Single High Dose - Adult |

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability.
After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| | |
|---|---|
| Reporting group title | PHASE 1B - Repeat Low Dose - Adult |

Reporting group description:

In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. in addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| | |
|---|---|
| Reporting group title | PHASE 1B - Repeat High Dose - Adult |

Reporting group description:

In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was

reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Single Low Dose - Adolescent |
|---|---|

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Single High Dose - Adolescent |
|---|---|

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.
After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.
Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

| Reporting group title | PHASE 1B - Repeat Low Dose - Adolescent |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.
All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 1B - Repeat High Dose - Adolescent |
|---|---|

Reporting group description:

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. in addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.
All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).
The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).
After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

| Reporting group title | PHASE 2A - Active AG019/teplizumab - Adults |
|---|---|

Reporting group description:

A total of 10 adult (18-40y) patients was enrolled into this arm.
The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.
Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).
After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

| Reporting group title | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults |
|---|---|

Reporting group description:

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).
All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

| Reporting group title | PHASE 2A - Active AG019/teplizumab - Adolescents |
|---|---|

Reporting group description:

10 adolescent (12-17y) patients was enrolled into this arm.
The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.
Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).
After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the .medical monitor.
After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 6 active patients and 1 placebo patient

| Reporting group title | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|

Reporting group description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.
Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).
All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).
Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 6 active patients and 1 placebo patient.

| **Serious adverse events** | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| **Serious adverse events** | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| **Serious adverse events** | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent | PHASE 2A - Active AG019/teplizumab - Adults |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |

| | | | |
|---|---|---|---|
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| **Serious adverse events** | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

Frequency threshold for reporting non-serious adverse events: 0 %

| **Non-serious adverse events** | PHASE 1B - Single Low Dose - Adult | PHASE 1B - Single High Dose - Adult | PHASE 1B - Repeat Low Dose - Adult |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 2 / 2 (100.00%) | 5 / 5 (100.00%) |
| Vascular disorders | | | |
| Pallor | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Administration site pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pruritus | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site related reaction | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Infusion site irritation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Cytokine release syndrome | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Selective IgA immunodeficiency | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|---|---|---|---|
| Dysmenorrhoea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scrotal irritation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vulvovaginal discomfort | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Painful respiration | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillar hypertrophy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |

| | | | |
|---|---|---|---|
| Anxiety | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Attention deficit hyperactivity disorder | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Panic attack | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood potassium increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Body temperature decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 2 (50.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eosinophil count increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epstein-Barr virus test positive | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint injury | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 2 (50.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ligament sprain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness postural | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tension headache | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythropenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Motion sickness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic gastritis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coeliac disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival bleeding | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tongue dry | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Erythema | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 2 (50.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scab | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Growing pains | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medial tibial stress syndrome | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle twitching | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Systemic lupus erythematosus | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Body tinea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 2 / 5 (40.00%) |
| occurrences (all) | 0 | 0 | 3 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 3 / 5 (60.00%) |
| occurrences (all) | 0 | 0 | 4 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 2 (50.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| **Non-serious adverse events** | PHASE 1B - Repeat High Dose - Adult | PHASE 1B - Single Low Dose - Adolescent | PHASE 1B - Single High Dose - Adolescent |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | 1 / 2 (50.00%) | 2 / 2 (100.00%) |
| Vascular disorders | | | |
| Pallor | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Administration site pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pruritus | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site related reaction | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion site irritation | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Cytokine release syndrome | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Selective IgA immunodeficiency | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Dysmenorrhoea | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scrotal irritation | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vulvovaginal discomfort | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Painful respiration | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillar hypertrophy | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Attention deficit hyperactivity disorder | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Panic attack | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood bilirubin increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood potassium increased | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Body temperature decreased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eosinophil count increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epstein-Barr virus test positive | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 5 (40.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count decreased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 5 (40.00%) | 1 / 2 (50.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint injury | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ligament sprain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth fracture | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 2 (50.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin laceration | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Cardiac disorders | | | |

| | | | |
|---|---|---|---|
| Palpitations | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tension headache | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythropenia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Motion sickness | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic gastritis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coeliac disease | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival bleeding | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tongue dry | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dermatitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Rash | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scab | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Growing pains | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medial tibial stress syndrome | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle twitching | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Systemic lupus erythematosus | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Body tinea | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 8 | 0 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| **Non-serious adverse events** | PHASE 1B - Repeat Low Dose - Adolescent | PHASE 1B - Repeat High Dose - Adolescent | PHASE 2A - Active AG019/teplizumab - Adults |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 4 / 4 (100.00%) | 4 / 5 (80.00%) | 10 / 10 (100.00%) |
| Vascular disorders | | | |
| Pallor | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| General disorders and administration site conditions | | | |
| Administration site pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pruritus | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site related reaction | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion site irritation | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pain | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 1 | 0 | 2 |
| Immune system disorders | | | |
| Cytokine release syndrome | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Selective IgA immunodeficiency | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Dysmenorrhoea | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scrotal irritation | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Vulvovaginal discomfort | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Dyspnoea exertional | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 1 | 0 | 6 |
| Painful respiration | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Tonsillar hypertrophy | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Attention deficit hyperactivity disorder | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Panic attack | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Suicidal ideation | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood potassium increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Body temperature decreased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Eosinophil count increased | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Epstein-Barr virus test positive | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 3 |
| Monocyte count decreased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Protein total increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Joint injury | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ligament sprain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Thermal burn | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin laceration | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 5 / 10 (50.00%) |
| occurrences (all) | 0 | 2 | 7 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Presyncope | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Tension headache | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Erythropenia | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 2 / 5 (40.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 3 | 2 | 3 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 2 | 0 | 1 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 6 |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 3 / 10 (30.00%) |
| occurrences (all) | 3 | 0 | 5 |
| Ear and labyrinth disorders | | | |
| Motion sickness | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tinnitus | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chronic gastritis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coeliac disease | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Constipation | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 4 / 10 (40.00%) |
| occurrences (all) | 1 | 0 | 4 |
| Dyspepsia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gingival bleeding | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Nausea | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 1 / 5 (20.00%) | 4 / 10 (40.00%) |
| occurrences (all) | 2 | 1 | 4 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Tongue dry | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Toothache | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 2 / 5 (40.00%) | 4 / 10 (40.00%) |
| occurrences (all) | 0 | 3 | 12 |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|---|---|---|
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 5 / 10 (50.00%) |
| occurrences (all) | 0 | 0 | 5 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Scab | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Growing pains | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Medial tibial stress syndrome | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle twitching | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 5 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 2 | 0 | 2 |
| Systemic lupus erythematosus | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Body tinea | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Infectious mononucleosis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Influenza | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Medical device site infection | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 3 / 10 (30.00%) |
| occurrences (all) | 0 | 0 | 3 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 2 / 5 (40.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 2 | 4 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 5 (20.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Viral infection | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Iron deficiency | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 5 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| **Non-serious adverse events** | PHASE 2A - AG019-placebo/teplizumab-placebo - Adults | PHASE 2A - Active AG019/teplizumab - Adolescents | PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 2 / 2 (100.00%) | 5 / 5 (100.00%) | 1 / 1 (100.00%) |
| Vascular disorders | | | |
| Pallor | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Administration site pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Catheter site pruritus | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Catheter site related reaction | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion site irritation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Immune system disorders | | | |
| Cytokine release syndrome | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Selective IgA immunodeficiency | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Reproductive system and breast disorders | | | |
| Dysmenorrhoea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scrotal irritation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vulvovaginal discomfort | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 2 / 5 (40.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Painful respiration | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillar hypertrophy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |

| | | | |
|---|---|---|---|
| Anxiety | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Attention deficit hyperactivity disorder | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Depression | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Panic attack | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood potassium increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Body temperature decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eosinophil count increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epstein-Barr virus test positive | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 2 / 5 (40.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Monocyte count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint injury | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ligament sprain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness postural | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 2 / 2 (100.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 11 | 3 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tension headache | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythropenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 2 / 2 (100.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Motion sickness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorders | | | |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic gastritis | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Coeliac disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival bleeding | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tongue dry | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 2 / 5 (40.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 5 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scab | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Growing pains | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medial tibial stress syndrome | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle twitching | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 2 / 5 (40.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Systemic lupus erythematosus | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infections and infestations | | | |
| Body tinea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 5 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 05 April 2018 | minor changes |
| 16 April 2018 | Staggered enrolment of single dose patients<br>Changes to I/E criteria requested internally and by central IRB<br>Clarification in description of assessments<br>Addition of HCV and HIV in infectious disease monitoring<br>Addition of insulin dose adjusted HbA1c<br>Addition of CGM<br>Addition of tuberculosis test |
| 08 October 2018 | Addition of upper age limit (40 years)<br>Clarification on the dose to be used in Phase 2a<br>Clarifications to I/E criteria<br>Addition of summary of non-clinical studies<br>Clarifications to assessments<br>Changes to grading and reporting of hypoglycemic and hyperglycemic events. |
| 11 April 2019 | Extension of screening period to 4 weeks<br>Addition of HBV to infectious disease monitoring<br>Change of Safety Management and pharmacovigilance vendor<br>Clarifications to assessments<br>Addition of Interim Analysis protocol section<br>Clarification to infusion withholding criteria |
| 19 September 2019 | Change to inclusion criteria and infusion withholding criteria (bilirubin)<br>Clarification on replacement of patients who cannot receive the first dose of teplizumab due to withholding criteria |
| 03 February 2020 | Clarification of assessments<br>Modification of infusion withholding criteria and criteria for suspension of enrollment |
| 11 June 2020 | Addition of SARS-Cov2 PCR test<br>Addition of interim analyses |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|---|---|---|

| | | |
|---|---|---|
| 30 August 2019 | In line with the protocol defined enrollment suspension criteria for teplizumab infusion withholding in >20% of exposed patients, enrollment was temporarily paused, pending data review by the DSMB. Data review was performed on 04-Sep-2019 and the DSMB subsequently confirmed that enrollment could resume. | 04 September 2019 |
| 11 October 2019 | In line with the protocol defined enrollment suspension criteria for teplizumab infusion withholding in >20% of exposed patients, enrollment was temporarily paused, pending data review by the DSMB. Data review was performed on 16-Oct-2019 and the DSMB subsequently confirmed that enrollment could resume. | 16 October 2019 |
| 18 March 2020 | After consulting with the DSMB, the Sponsor decided to temporarily suspend enrollment of new patients into the study due to the COVID-19 pandemic. In the following mnths, the Sponsor has generated a set of measures to protect the safety and well being of all study patients, and to ensure the integrity of the data. These included, amongst others, generation of a protocol amendment, generation of a checklist for reopening sites on a case-by-case basis, taking measures to allow for remote data monitoring, taking measures to enable home healthcare visits for study patients, and reinforcing the DSMB with 2 infectious disease experts. On 24-Jun-2020 all measures were presented to the DSMB, who concluded that enrollment could resume on a site-by-site basis, provided that all required measures were in place. | 24 June 2020 |

Notes:

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

| |
|---|
| As this was a first in human study, it was exclusively designed to demonstrate the safety and tolerability of AG019 (alone and in association with teplizumab). It was not powered to demonstrate efficacy (sample size too low). |

Notes: